Infutraze

Zinc chloride, potassium iodide, sodium selenite, copper chloride dihydrate, and manganese chloride tetrahydrate, the active ingredients in Infutraze, are trace element supplements presented as an intravenous solution for parenteral nutrition use. They help correct trace element deficiencies in patients receiving total parenteral nutrition or who have increased metabolic demands.

GNH USA supplies Infutraze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to clinical nutrition teams across continents.

Infutraze is used to address trace element deficiencies in patients receiving parenteral nutrition. - Trace element deficiency: restores essential zinc, iodine, selenium, copper, and manganese levels to support enzymatic activity. - Total parenteral nutrition (TPN): provides a balanced trace element profile to complement macronutrient solutions. - Post‑operative recovery: helps prevent deficiency‑related complications in patients unable to take oral nutrition. - Critical illness: supports metabolic processes in intensive care patients receiving intravenous feeding.

Infutraze may be associated with infusion‑related reactions and, rarely, systemic toxicities.

Common Side Effects: - Infusion site erythema: redness at the injection site. - Mild nausea: transient feeling of queasiness. - Headache: low‑grade headache during or after infusion.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical intervention. - Electrolyte imbalance: abnormal serum copper or zinc levels causing organ dysfunction. - Selenium toxicity: respiratory distress or gastrointestinal upset in cases of excess.

When using Infutraze, clinicians should observe several precautions to minimize risks. - Assess baseline trace element status: obtain serum levels before initiating therapy. - Monitor serum electrolytes: check zinc, copper, selenium, manganese, and iodine concentrations regularly. - Adjust dose in renal or hepatic impairment: reduce infusion rate if organ function is compromised. - Avoid concurrent high‑dose trace element supplements: prevent cumulative toxicity. - Observe for infusion reactions: be prepared to stop infusion and treat symptoms if they occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infutraze can interact with certain medications and supplements; awareness of these interactions helps ensure safe administration.

Major Interactions (Avoid): - High‑dose copper chelators (e.g., penicillamine): may markedly reduce copper availability. - Excessive iodine‑containing contrast agents: can lead to iodine overload and thyroid dysfunction.

Moderate Interactions (Monitor Closely): - Parenteral vitamin C solutions: may increase copper excretion and affect balance. - Anticoagulants (heparin): trace elements can potentiate bleeding risk; monitor coagulation parameters. - Other trace element preparations: combined use may cause cumulative toxicity; adjust dosing accordingly.